2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1003

TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1167

To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1244

Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1181

Tocilizumab in Aortitis: A Multicenter Study of 79 Patients

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 986

Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1444

Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1738

Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 988

Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1389

Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1237

Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1404

Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1097

Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1335

Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1518

Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1019

Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts

SLE – Etiology & Pathogenesis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].